Insights

National expansion OrganaBio has rapidly expanded its geographic footprint through the Excellos acquisition and new PBMC processing labs in California, signaling a strategic move to serve coast-to-coast cell therapy developers and clinical trial sponsors with rapid processing capabilities.

End-to-end services The company offers a full development lifecycle from tissue sourcing and starting materials to development, testing, and support services, creating turnkey partnerships attractive to biotechs seeking a single vendor for multiple CDMO needs.

Strategic partnerships Recent manufacturing agreements with RxMP Therapeutics for RMP-402 and the acquisition of Excellos assets position OrganaBio as a key partner for cGMP production and technology transfer in hemostatic drug development.

Clinical sample speed Launch of time-sensitive PBMC isolation and cryopreservation capabilities in Southern California enhances competitiveness for sponsors requiring rapid, high-viability cell processing, a potential differentiator for trial timelines.

Growth signals Revenue banding ($10M-$25M) combined with active fundraising activity and expansion suggests organaBio is scaling; sales motions can focus on multi-site CDMO service packages, capacity planning, and long-term supply agreements with mid-market biotechs looking for reliable partners.

Similar companies to OrganaBio

OrganaBio Tech Stack

OrganaBio uses 8 technology products and services including LinkedIn Ads, Microsoft Advertising, NetSuite, and more. Explore OrganaBio's tech stack below.

Media & News

OrganaBio's Email Address Formats

OrganaBio uses at least 4 email formats:
OrganaBio Email FormatsExamplePercentage
First.Last@organabio.comJohn.Doe@organabio.com
79%
First@organabio.comJohn@organabio.com
13%
Last@organabio.comDoe@organabio.com
7%
First_Last@organabio.comJohn_Doe@organabio.com
1%

Frequently Asked Questions

What is OrganaBio's official website and social media links?

Minus sign iconPlus sign icon
OrganaBio's official website is organabio.com and has social profiles on LinkedIn.

How much revenue does OrganaBio generate?

Minus sign iconPlus sign icon
As of October 2026, OrganaBio's annual revenue is estimated to be $10M - $25M.

What is OrganaBio's SIC code and NAICS code?

Minus sign iconPlus sign icon
OrganaBio's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does OrganaBio have currently?

Minus sign iconPlus sign icon
As of October 2026, OrganaBio has approximately 26 employees across 3 continents, including North America, Asia and Europe. Key team members include Senior Director, Tissue Procurement: T. C., Manager , Business Development: E. F. and Cell Processing Associate: N. P. Explore OrganaBio's employee directory with LeadIQ.

What industry does OrganaBio belong to?

Minus sign iconPlus sign icon
OrganaBio operates in the Biotechnology Research industry.

What technology does OrganaBio use?

Minus sign iconPlus sign icon
OrganaBio's tech stack includes LinkedIn Ads, Microsoft Advertising, NetSuite, Shopify, WooCommerce, Microsoft 365, Microsoft Teams and Piwik PRO Core.

What is OrganaBio's email format?

Minus sign iconPlus sign icon
OrganaBio's email format typically follows the pattern of First.Last@organabio.com. Find more OrganaBio email formats with LeadIQ.

When was OrganaBio founded?

Minus sign iconPlus sign icon
OrganaBio was founded in 2018.
OrganaBio logo

OrganaBio

Biotechnology ResearchFlorida, United States11-50 Employees

OrganaBio is a biotechnology company founded in 2018 and headquartered in Miami, Florida. It functions as a hub for tissue sourcing, clinical sample processing, and contract manufacturing services that support developers of cell and gene therapies globally. The firm emphasizes a data-driven approach across its strategically located facilities to deliver solutions where clients need them most. Its scope spans the development lifecycle, from proprietary tissue supply chains and cellular starting materials to development, testing, and other support activities intended to accelerate clinical translation. It operates a network of cell processing and cryopreservation laboratories across multiple U.S. locations.

Its customer base includes cell and gene therapy developers and clinical trial sponsors seeking GMP-grade starting materials and related manufacturing or support services. In 2024 it announced the launch of HematoPAC, a cGMP-compliant hematopoietic stem cell product ethically derived from cord blood. The company has expanded its footprint, opening a Hayward, California facility in 2025 and, in 2026, expanding to San Diego by acquiring assets from Excellos to create a coast-to-coast CDMO presence with autologous and allogeneic cell therapy capabilities. Its west coast labs in San Francisco and Irvine complement the Miami headquarters and other facilities, reflecting a nationwide network.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2018
Employees
11-50

Section iconFunding & Financials

  • $10M - $25M

    OrganaBio's revenue is estimated to be in the range of $10M - $25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.